Table 2 FibriCheck overall performance
From: Fibricheck detection capabilities for atrial fibrillation (FDA–AF): a multicenter validation study
Overall performance | FibriCheck without verification | FibriCheck with verification | ||||
|---|---|---|---|---|---|---|
Group | All | US | Non-US | All | US | Non-US |
Accuracy (95% CI) | 98.5% (98.0–99.0%) | 98.3% (97.5–98.9%) | 99.1% (98.0–99.6%) | 98.8% (98.2–99.2%) | 98.2% (97.4–98.8%) | 99.9% (99.2–100%) |
Sensitivity (95% CI) | 96.3% (94.4–97.7%) | 95.1% (92.2–97.2%) | 98.0% (95.3–99.3%) | 99.0% (97.7–99.6%) | 98.2% (96.1–99.3%) | 100% (98.5–100%) |
Specificity (95% CI) | 99.3% (98.8–99.7% | 99.2% (98.5–99.6%) | 99.6% (98.5–100%) | 98.7% (98.0–99.2%) | 98.3% (97.3–98.9%) | 99.8% (98.8–100%) |
Disease prevalence | 26.1% | 22.2% | 33.8% | 26.2% | 22.3% | 34.0% |
PPV (95% CI) | 98.0% (96.5–98.9%) | 97.2% (94.7–98.5%) | 99.2% (96.8–99.8%) | 96.4% (94.7–97.6%) | 94.1% (91.2–96.1%) | 99.6% (97.2–99.9%) |
Prevalence-adjusted PPV, 6% | 90.1% (83.4–94.2%) | 88.5% (80.1–93.7%) | 93.8% (79.0–98.4%) | 82.9% (76.1–88.2%) | 78.1% (69.8–84.7%) | 96.8% (81.2–99.5%) |
NPV (95% CI) | 98.7% (98.1–99.2%) | 98.6% (97.8–99.1%) | 99.0% (97.6–99.6%) | 99.6% (99.2–99.8%) | 99.5% (98.8–99.8%) | 100% (99.2–100%) |
Prevalence-adjusted NPV, 6% | 99.8% (99.6–99.9%) | 99.7% (99.5–99.8%) | 99.5% (98.7–99.9%) | 99.9% (99.9–100%) | 99.9% (99.7–100%) | 100% (99.2–100%) |
